CRBN and plasma cell myeloma: Although acting on the E3 ligase-related function of CRBN appears to be the main mechanism for the anti-myeloma activity of IMiDs [12,13], recent reports indicate that IMiDs also act by modulating other properties of CRBN, such as chaperone function [14,15].